1. Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE
    Malkhaz Mizandari et al, 2017, Immunotherapy CrossRef
  2. Impact of Interventional Oncology Therapies on Tumor Microenvironment and Strategies to Enhance Their Efficacy
    Stacy K. Y. Fan et al, 2018, American Journal of Roentgenology CrossRef
  3. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC)
    Venkata K. Pokuri et al, 2018, American Journal of Clinical Oncology CrossRef
  4. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases
    Manouchehr Teymouri et al, 2018, Int. J. Cancer CrossRef
  5. null
    Christos Fountzilas et al, 2019 CrossRef
  6. Efficacy of interferon therapy in patients with hepatitis B virus-related primary hepatic carcinoma after transcatheter arterial chemoembolization
    Meng Xin et al, 2018, Prec. Radiat. Oncol. CrossRef
  7. Combined locoregional-immunotherapy for liver cancer.
    Tim F Greten et al, 2019, J Hepatol CrossRef
  8. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper
    Joseph P. Erinjeri et al, 2019, Radiology CrossRef
  9. Interleukin-35 Dampens CD8+ T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma
    Lanlan Yang et al, 2019, Front. Immunol. CrossRef
  10. Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma
    Rony Avritscher et al, 2019, Cardiovasc Intervent Radiol CrossRef
  11. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
    Maria Tampaki et al, 2020, Cancers CrossRef
  12. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma
    Hana Park et al, 2020, Hepatol Int CrossRef

  13. Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization


    Hongyu Wang et al, 2020, CMAR CrossRef
  14. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Peng Zeng et al, 2020, Curr Oncol Rep CrossRef
  15. null
    Johannes Maximilian Ludwig et al, 2020 CrossRef
  16. Therapeutic Efficacy of Delta-Like Ligand 4 Gene Vaccine Overexpression on Liver Cancer in Mice
    Yi Yu et al, 2020, Technol Cancer Res Treat CrossRef
  17. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma.
    Ahmed Montasser et al, 2021, Histopathology CrossRef
  18. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
    Matthias Ocker et al, 2021, Cancers CrossRef
  19. Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Sung Won Chung et al, 2021, JHC CrossRef
  20. Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors
    Jacinth Wing‐Sum Cheu et al, 2021, Hepatology CrossRef
  21. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
    Antonio D'Alessio et al, 2021, JHC CrossRef
  22. Immunotherapy in Hepatocellular Carcinoma.
    Claudia A M Fulgenzi et al, 2021, Curr Treat Options Oncol CrossRef
  23. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
    Ji-Won Han et al, 2021, Pharmaceutics CrossRef
  24. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor
    Qin Shi et al, 2021, CMAR CrossRef
  25. Changes of immune cells in patients with hepatocellular carcinoma treated by radiofrequency ablation and hepatectomy, a pilot study
    Zusheng Yu et al, 2021 CrossRef
  26. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
    Bao-Jiang Liu et al, 2021, Immunotherapy CrossRef
  27. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions
    Xiao-Wan Bo et al, 2021, WJGO CrossRef
  28. Changes in immune profile affect disease progression in hepatocellular carcinoma
    Farshid Fathi et al, 2022, Int J Immunopathol Pharmacol CrossRef
  29. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
    Yaoqiang Wu et al, 2022, Front. Oncol. CrossRef
  30. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand‐1 in advanced hepatocellular carcinoma patients
    Ma Xiaochen et al, 2022, Asia-Pac J Clncl Oncology CrossRef
  31. The Molecular Role of IL-35 in Non-Small Cell Lung Cancer
    Yuqiu Hao et al, 2022, Front. Oncol. CrossRef
  32. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
    Xue-Gang Yang et al, 2022, Front. Immunol. CrossRef
  33. Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge
    Anna Sessa et al, 2022, JHC CrossRef
  34. Histological tumor micronecrosis in resected specimens after R0 hepatectomy for hepatocellular carcinomas is a factor in determining adjuvant TACE: A retrospective propensity score-matched study
    Yangyang Wang et al, 2022, International Journal of Surgery CrossRef
  35. Establishment of Nomogram Model for Minimally Invasive Treatment of Small Hepatocellular Carcinoma Based on CD8+T Cell Counts
    Qing Pu et al, 2022, OTT CrossRef
  36. Variation of NK, NKT, CD4+ T, CD8+ T cells, and IL-17A by CalliSpheres® microspheres-transarterial chemoembolization in refractory liver metastases patients
    Guangsheng Zhao et al, 2022, Scandinavian Journal of Clinical and Laboratory Investigation CrossRef
  37. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Qian Li et al, 2022, Front. Immunol. CrossRef
  38. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study
    Luyun Yuan et al, 2023, European Journal of Surgical Oncology CrossRef
  39. Correlation of serum chemokine 14 with Barcelona Clinic Liver Cancer Stage, Lymphocyte Profile, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
    Yuan Guo et al, 2023, Journal of Vascular and Interventional Radiology CrossRef
  40. Immune checkpoint inhibition: a future guided by radiology
    Faraaz Khan et al, 2023, BJR CrossRef
  41. Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
    Alessandro Posa et al, 2023, IJMS CrossRef
  42. TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial
    Weili Qi et al, 2023, Front. Oncol. CrossRef
  43. Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies; a rapidly evolving strategy
    Marzieh Nikoo et al, 2023, Pathology - Research and Practice CrossRef
  44. PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma
    Petros Fessas et al, 2023, Future Oncology CrossRef
  45. Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies
    Jonathan Charles et al, 2023, Cancers CrossRef
  46. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
    Nicolò Brandi et al, 2023, IJMS CrossRef
  47. Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo‐Immuno‐Embolization for the Treatment of Hepatocellular Carcinoma
    Heegon Kim et al, 2023, Adv Healthcare Materials CrossRef
  48. Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
    Shamar Young et al, 2023, IJMS CrossRef
  49. Unexpected anti-tumor effect of immune checkpoint inhibitors followed by transcatheter arterial chemoembolization for hepatocellular carcinoma
    Yoshiaki Ando et al, 2023, Clin J Gastroenterol CrossRef
  50. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Liwei Deng et al, 2024, JHC CrossRef
  51. Immune Effects of Intra-Arterial Liver-Directed Therapies
    Anita Karimi et al, 2024, Journal of Vascular and Interventional Radiology CrossRef
  52. Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
    Jiahao Li et al, 2024, Life Sciences CrossRef
  53. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors
    Huimin Zou et al, 2024, International Immunopharmacology CrossRef